Ghrelin, a novel peptide hormone in the regulation of energy balance and cardiovascular function

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 5, Issue 1, 2011, Pages 1-6

  Ledderose, Carola ^a,b   Kreth, Simone ^a   Beiras Fernandez, Andres ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cachexia; Chronic heart failure; Energy metabolism; Ghrelin; Obesity; Patents

Indexed keywords

GHRELIN; GHRELIN RECEPTOR;

ARTICLE; BIOSYNTHESIS; CACHEXIA; CARDIOVASCULAR FUNCTION; CHRONIC LUNG DISEASE; ENERGY BALANCE; HEART FAILURE; HEART PROTECTION; HUMAN; INFECTION; MALNUTRITION; OBESITY; PRIORITY JOURNAL; WASTING SYNDROME;

CACHEXIA; CARDIOVASCULAR SYSTEM; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; ENERGY METABOLISM; GHRELIN; HEART FAILURE; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; OBESITY; PATENTS AS TOPIC; RECEPTORS, GHRELIN;

EID: 79551619646     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221411794351897     Document Type: Article

References (58)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004; 291: 1238-45.
2. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
3. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-8.
4. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-13.
5. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya A, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1483-7.
6. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57-66.
7. Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000; 276: 905-8.
8. Castaneda TR, Tong J, Datta R, Culler M, Tschop MH. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol 2010; 31: 44-60.
9. Romero A, Kirchner H, Heppner K, Pfluger PT, Tschop MH, Nogueiras R. GOAT: the master switch for the ghrelin system? Eur J Endocrinol 2010; 163: 1-8.
10. Tesauro M, Schinzari F, Caramanti M, Lauro R, Cardillo C. Metabolic and cardiovascular effects of ghrelin. Int J Pept 2010. (in press) doi:10.1155/2010/864342.
11. Ueno H, Shiiya T, Nakazato M. Translational research of ghrelin. Ann NYAcad Sci 2010; 1200: 120-7.
12. Sakata I, Nakamura K, Yamazaki M, Matsubara M, Hayashi Y, Kangawa K, et al. Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 2002; 23: 531-6.
13. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988.
14. Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008; 132: 387-96.
15. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000; 85: 4908-11.
16. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992.
17. Papotti M, Ghe C, Cassoni P, Catapano F, Deghenghi R, Ghigo E, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 2000; 85: 3803-7.
18. Espelund U, Hansen TK, Orskov H, Frystyk J. Assessment of ghrelin. APMIS Suppl 2003; (109): 140-5.
19. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3- kinase/AKT. J Cell Biol 2002; 159: 1029-37.
20. Li L, Zhang LK, Pang YZ, Pan CS, Qi YF, Chen L, et al. Cardioprotective effects of ghrelin and des-octanoyl ghrelin on myocardial injury induced by isoproterenol in rats. Acta Pharmacol Sin 2006; 27: 527-35.
21. Popovic V, Miljic D, Micic D, Damjanovic S, Arvat E, Ghigo E, et al. Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab 2003; 88: 3450-3.
22. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Chronic central infusion of ghrelin increaseshypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 2001; 50: 2438-43.
23. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997; 278: 135-8.
24. Tschop M, Statnick MA, Suter TM, Heiman ML. GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology 2002; 143(2): 558-68.
25. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001; 86: 5083-6.
26. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-9.
27. Tschop M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001; 24: RC19-21.
28. Foster-Schubert KE, Overduin J, Prudom CE, Liu J, Callahan HS, Gaylinn BD, et al. Acyl and total ghrelin are suppressed strongly by ingested proteins, weakly by lipids, and biphasically by carbohydrates. J Clin Endocrinol Metab 2008; 93: 1971-9.
29. Jensen MD. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring) 2006; 14 (Suppl 3): 143S-9.
30. Wortley KE, del Rincon JP, Murray JD, Garcia K, Iida K, Thorner MO, et al. Absence of ghrelin protects against early-onset obesity. J Clin Invest 2005; 115: 3573-8.
31. Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005; 115: 3564-72.
32. Bowers, C.Y., Coy, D.H., Hocart, S.J. Ghrelin/growth hormone releasing peptide/growth hormone secretagogue receptor antagonists and uses thereof. US20090069245 (2009).
33. Fraser, G.L. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same. US20090275648 (2009).
34. Min, G. E, Yang, S.G.M. Substituted pyrazoles as ghrelin receptor antagonists. US20090253673 (2009).
35. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-9.
36. Jarosch, F., Maasch, C., Helmling, S., Klussmann, S. Ghrelin binding nucleic acids. US20060258607 (2006).
37. Helmling, S., Eulberg, D.,Maasch, C., Klussmann, S. Ghrelin binding nucleic acids. US7750140 (2010).
38. Marquis, D.M., Subramaniam, D.R., Witcher, D.R. Humanized anti-ghrelin antibodies. US20090181018 (2009).
39. Harran, P.G., Goldstein, J.L., Yang, J., Zhao, T.J. Small molecule inhibitors of ghrelin O-acyltransferase. US20100086955 (2010).
40. Ashitani J, Matsumoto N, Nakazato M. Ghrelin and its therapeutic potential for cachectic patients. Peptides 2009; 30: 1951-6.
41. Rodriguez, F., Estrada, G. M.P., Martinez, R. R., Chinea, S. G., Reyes, A. O., Fernandez, M. J.R., Garcia del Barco, H. D., Berlanga, A. J.A., Musacchio, L. A. Compounds analogous to growth hormone peptide secretagogues and preparations containing them. EP1997827 (2006).
42. Mintz, L. Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation. US20090043074 (2009).
43. Ono, A., Morita, Y., Serizawa, A., Higurashi, S. Growth hormone secretion stimulator. EP2133090 (2008) & US20100087372 (2010).
44. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104: 1430-5.
45. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110: 3674-9.
46. Lin Y, Matsumura K, Fukuhara M, Kagiyama S, Fujii K, Iida M. Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 2004; 43: 977-982.
47. Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: Ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002; 136: 1146-52.
48. Iantorno M, Chen H, Kim JA, Tesauro M, Lauro D, Cardillo C, et al. Ghrelin has novel vascular actions that mimic PI 3-kinasedependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 2007; 292: E756-64.
49. Xu X, Jhun BS, Ha CH, Jin ZG. Molecular mechanisms of ghrelinmediated endothelial nitric oxide synthase activation. Endocrinology 2008; 149: 4183-92.
50. Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005; 112: 2986-92.
51. Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 1999; 140: 4024-31.
52. Yang R, Bunting S, Gillett N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995; 92: 262-7.
53. Iglesias MJ, Pineiro R, Blanco M, Gallego R, Dieguez C, Gualillo O, et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res 2004; 62: 481-8.
54. Brizzi, M., Ghigo, E. Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease. US20100016226 (2010).
55. Locatelli, V., Bresciani, E., Bulgarelli, I., Tamiazzo, L., Ravelli, M. Use of growth hormone secretagogues to block or inhibit the reninangiotensin system. WO2008041106 (2008).
56. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, et al. Ghrelin inhibits proinflammatory responses and nuclear factorkappaB activation in human endothelial cells. Circulation 2004; 109: 2221-6.
57. Dong ZX, Culler MD, Datta R. Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue. WO2009020643 (2009).
58. Beiras-Fernandez A, Kreth S, Weis F, Ledderose C, Pottinger T, Dieguez C, et al. Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients with severe heart failure. Peptides 2010; 31: 2222-8.